Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

12 questions in 3 reviews

current versions

No studies 0 · 0%Ungraded 2 · 16.7%Very low 1 · 8.3%Low 8 · 66.7%Moderate 1 · 8.3%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Antidepressant vs placebo Treatment success · Children and adolescents with functional abdominal pain disorder Antidepressants for functional abdominal pain disorders in children and adolescents (2021) · Cochrane	RR 1.17 [0.87, 1.56]	2 studies · 205 participants	Low
Antidepressant vs placebo Withdrawals due to adverse events · Children and adolescents with functional abdominal pain disorder Antidepressants for functional abdominal pain disorders in children and adolescents (2021) · Cochrane	RR 3.17 [0.65, 15.33]	3 studies · 238 participants	Low
Tricyclic antidepressants (TCAs) vs placebo Efficacy for ADHD symptoms (parents using a rating scale) ‐ desipramine · Children and adolescents with ADHD Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents (2014) · Cochrane	no estimate extracted	2 studies · 99 participants	Low
Tricyclic antidepressants (TCAs) vs placebo Efficacy for ADHD symptoms (teachers using a rating scale) ‐ desipramine · Children and adolescents with ADHD Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents (2014) · Cochrane	no estimate extracted	2 studies · 89 participants	Low
Tricyclic antidepressants (TCAs) vs placebo CGI (response rate) ‐ desipramine and nortriptyline · Children and adolescents with ADHD Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents (2014) · Cochrane	OR 18.5 [6.29, 54.39]	3 studies · 125 participants	Low
Tricyclic antidepressants (TCAs) vs placebo Clinical global impression (response rate) ‐ desipramine · Children and adolescents with ADHD Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents (2014) · Cochrane	OR 26.41 [7.41, 94.18]	2 studies · 103 participants	Low
Tricyclic antidepressants (TCAs) vs placebo All‐cause treatment discontinuation ‐ desipramine · Children and adolescents with ADHD Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents (2014) · Cochrane	no estimate extracted	3 studies · 134 participants	Very low
Second generation antidepressant vs placebo (by medication) Depressive disorder according to DSM or ICD criteriaClinician diagnostic interview · patients with depressive disorders in children and adolescents Newer generation antidepressants for depressive disorders in children and adolescents (2012) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Second generation antidepressant vs placebo (by medication) Suicide completionCompleted suicide rates · patients with depressive disorders in children and adolescents Newer generation antidepressants for depressive disorders in children and adolescents (2012) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Second generation antidepressant vs placebo (by medication) Remission or response (as defined in trial) · patients with depressive disorders in children and adolescents Newer generation antidepressants for depressive disorders in children and adolescents (2012) · Cochrane	RR 1.18 [1.08, 1.28]	16 studies · 2924 participants	Moderate
Second generation antidepressant vs placebo (by medication) Suicide‐related outcome · patients with depressive disorders in children and adolescents Newer generation antidepressants for depressive disorders in children and adolescents (2012) · Cochrane	RR 1.58 [1.02, 2.45]	17 studies · 3229 participants	Low
Second generation antidepressant vs placebo (by medication) Depressive symptom severityCDRS‐R. Scale from: 17 to 113. · patients with depressive disorders in children and adolescents Newer generation antidepressants for depressive disorders in children and adolescents (2012) · Cochrane	no estimate extracted	14 studies · 2490 participants	Low